| Date Filed | Type | Description |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/17/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 08/10/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 8.2% stake in Forte Biosciences, Inc. |
| 07/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Unicycive Therapeutics, Inc. |
| 06/30/2023 |
SC 13D/A
| BIOTECHNOLOGY VALUE FUND L P reports a 35.8% stake in MoonLake Immunotherapeutics |
| 06/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 7.1% stake in Revolution Medicines, Inc. |
| 06/28/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on CTI BIOPHARMA CORP|
Txns:
| Unknown transaction of 3,989,130 shares
@ $9.1, valued at
$36.3M
Unknown transaction of 2,595,239 shares
@ $9.1, valued at
$23.6M
Unknown transaction of 702,505 shares
@ $9.1, valued at
$6.4M
Unknown transaction of 1,526,147 shares
@ $9.1, valued at
$13.9M
Unknown transaction of 43,139 shares
@ $9.1, valued at
$392.6k
Unknown transaction of 1,594 options to buy
@ $0
Unknown transaction of 1,250 options to buy
@ $0
Unknown transaction of 191 options to buy
@ $0
Unknown transaction of 12 options to buy
@ $0
Unknown transaction of 344 options to buy
@ $0
Unknown transaction of 239 options to buy
@ $0 |
|
| 06/12/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on MoonLake Immunotherapeutics|
Txns:
| Granted 11,297 options to buy
@ $29.18, valued at
$329.6k
|
|
| 05/30/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 9.8% stake in Janux Therapeutics, Inc. |
| 05/19/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on XOMA Corp|
Txns:
| Granted 10,967 options to buy
@ $21.39, valued at
$234.6k
|
|
| 05/12/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on Structure Therapeutics Inc.|
Txns:
| Disposed of 4,018,253 shares
@ $0
Disposed of 2,929,660 shares
@ $0
Disposed of 462,605 shares
@ $0
Acquired 4,018,253 options to buy
@ $0
Acquired 2,929,660 options to buy
@ $0
Acquired 462,605 options to buy
@ $0 |
|
| 05/09/2023 |
4
| BVF PARTNERS L P/IL (10% Owner) has filed a Form 4 on Eledon Pharmaceuticals, Inc.|
Txns:
| Bought 1,055,445 shares
@ $0
Bought 837,146 shares
@ $0
Bought 86,341 shares
@ $0
Bought 2,028,645 options to buy
@ $0.001, valued at
$2k
Bought 1,609,063 options to buy
@ $0.001, valued at
$1.6k
Bought 165,950 options to buy
@ $0.001, valued at
$166
Bought 3,084,090 options to buy
@ $3, valued at
$9.3M
Bought 2,446,209 options to buy
@ $3, valued at
$7.3M
Bought 252,291 options to buy
@ $3, valued at
$756.9k
|
|
| 03/24/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in IDEAYA Biosciences, Inc. |
| 03/20/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 03/16/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P reports a 5% stake in Aclaris Therapeutics, Inc. |
| 03/06/2023 |
SC 13G
| BIOTECHNOLOGY VALUE FUND L P has filed a Schedule 13D for ASLAN Pharmaceuticals Limited |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 12.6% stake in Molecular Partners AG |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 4.6% stake in IDEAYA Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.9% stake in Galmed Pharmaceuticals Ltd. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.4% stake in Merus N.V. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 6.5% stake in 89bio, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.7% stake in POINT Biopharma Global Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.1% stake in Crinetics Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 3.2% stake in Arcus Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Relmada Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 1.4% stake in Cogent Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 16.4% stake in Cullinan Oncology, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 2.1% stake in Syndax Pharmaceuticals, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10.5% stake in Calliditas Therapeutics AB |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 10% stake in Calithera Biosciences, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 0% stake in Spero Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 8.1% stake in AN2 Therapeutics, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.8% stake in Sutro Biopharma, Inc. |
| 02/14/2023 |
SC 13G/A
| BIOTECHNOLOGY VALUE FUND L P reports a 5.6% stake in Viridian Therapeutics, Inc. |
|